Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Elut...( Report of Positive Results with Innov...),Health

Report of Positive Results with Innovative Pro-Healing Stent is Featured at

ESC Congress 2007

VIENNA, Austria, Sept. 3 /PRNewswire/ -- OrbusNeich today announced that post-marketing data from patient subsets of a global registry support the use of the company's Genous(TM) Bio-engineered R stent(TM) as an alternative to drug-eluting stents.

Presented today by Robbert de Winter, M.D., Ph.D., at the European Society of Cardiology (ESC) Congress 2007 in Vienna, Austria, the data from OrbusNeich's e-HEALING registry show:

* For 296 diabetic patients at six months, the target lesion

revascularization (TLR) rate was 2%, which is much lower than was

anticipated

* A TLR rate of 1.9% for 213 chronic total occlusion (CTO) patients at ]

six months

* For 923 patients with statin use, the major adverse cardiac events

(MACE) rate at six months was 5.7%, while 116 patients without statin

use experienced a MACE rate of 6.9% over the same period

"This real-world data strengthen our belief that Genous is a very promising alternative to drug-eluting stents," said de Winter, a co-principal investigator of the study and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. "Genous appears to have the same efficacy as drug-eluting stents but a better safety profile with only minimal dual-antiplatelet therapy requirements. This is an important finding in that physicians are becoming reluctant to burden their patients with the cost and compliance issues associated with drug-eluting stents and their extensive dual-antiplatelet therapy requirements."

OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United States) prospective registry of patients treated with the Genous Bio- engineered R stent in accordance with the instructions for use. The protocol recommends that patients receive two weeks of statin treatment prior t
'/>"/>